AstraZeneca has withdrawn the regulatory submissions for the use of Zactima (vandetanib), a potential non-small cell lung cancer treatment, based on new information.
The company withdrew its submissions for Zactima (vandetanib) 100mg in combination with chemotherapy from the US Food and Drug Administration and the European Medicines Agency after the drug showed no overall survival advantage.
Go deeper with GlobalData
Vandetanib showed no overall survival advantage when added to chemotherapy and preliminary feedback from the regulatory agencies also indicated that designating progression-free survival as the primary endpoint may not be sufficient for approval.
AstraZeneca has announced that it will complete the ongoing Phase III trial programme, which is expected to give a more complete view of vandetanib’s efficacy in different clinical settings.
Results from this study are expected in late 2009 or early 2010.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
